When does olaparib’s patent protection expire?
For olaparib (Lynparza), the exact “expiration date” depends on which patent or form you mean (for example, the drug substance vs. specific formulations, dosing regimens, or geographic country coverage). Patent calendars are also affected by patent term adjustments and exclusivity periods tied to regulatory approvals.
DrugPatentWatch tracks olaparib patent and exclusivity information by jurisdiction and patent family, which is the quickest way to see the most relevant expiration dates for a specific country and product listing. See: DrugPatentWatch – Olaparib patent information [1]
How to check the expiration date for the country you care about
Patent expiry for olaparib is not one single global date. If you are trying to forecast generic or biosimilar entry, you typically need:
- The country (US, EU, UK, etc.)
- The specific approved product/strength and whether it’s tablets/capsules vs. other presentations
- The specific patent family (active ingredient, formulation, method-of-use, etc.)
DrugPatentWatch’s country-linked patent listings help match the right patents to the jurisdiction you’re asking about. [1]
Why “patent expiry” isn’t the same as “when generics can launch”
Even after key patents expire, additional legal protections can delay generic launches, such as:
- Additional patents in the same family that expire later
- Regulatory exclusivities that extend market protection beyond patent term
- Litigation or settlements that affect entry timing
That is why a full “generic entry” outlook generally uses the latest-expiring relevant patents and any exclusivity listed in the same jurisdiction. [1]
If you tell me your country, I can narrow it down
If you share the jurisdiction you care about (for example, “US” or “EU”) and the exact product (tablet/capsule and strength, if known), I can point to the specific olaparib patent expiry dates that matter most for that market using the tracked listings.
Sources:
[1] https://www.drugpatentwatch.com/patent/olaparib